knowledge -WSS

knowledge

author：fashion 2025-10-02 04:08:15 - browse：16869

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Bird flu makes raw milk dangerous to consume, mouse study finds

focus

WSS

Mass General totes up its waste in a move to tackle climate change

Achieving telehealth equity for people with hearing loss

U.S. death rates show how politics are affecting public health

Texas Department of Public Safety speaks out on migrant abuse allegations

Tesla recalling nearly 16,000 of its 2021

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

leisure time

knowledge

explore

Apple is now the first public company to be valued at $3 trillion

I learned firsthand about improving diversity in clinical trials

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Stanford president's case begs question: Who takes blame?

Cancer drug shortages should be causing more outrage

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Medicare details structure of new drug price negotiation program

The Bio Revolution is changing business and society

Jerome Adams on the need for new antivirals for Covid

Lawsuit challenges CMS nursing home minimum staffing rule

focus

Indian pharmaceutical industry in denial over drug

Medical students need to learn the potent medicine of empathy

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

J&J reports mixed data on next

Why some fertility treatments produce more boy babies

J&J reports mixed data on next

hotspot

focus

focus

leisure time